<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111075">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070965</url>
  </required_header>
  <id_info>
    <org_study_id>BDS1307</org_study_id>
    <nct_id>NCT02070965</nct_id>
  </id_info>
  <brief_title>DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <acronym>BDS1307</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Promius Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promius Pharma, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA
      (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily
      for 15 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects with HPA axis suppression</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>DFD01 Spray Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD01 Spray, bid, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comp01 Lotion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comp01 Lotion, bid, 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFD01 Spray Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD01 Spray, bid, 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD01 Spray</intervention_name>
    <arm_group_label>DFD01 Spray Group 1</arm_group_label>
    <arm_group_label>DFD01 Spray Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comp01 Lotion</intervention_name>
    <arm_group_label>Comp01 Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque
             psoriasis.

          2. Subjects with psoriasis involving 20 to 50% BSA, not including the face, scalp,
             groin, axillae and other intertriginous areas.

          3. Subjects must have an IGA grade of at least 3 (moderate) at the Baseline Visit

          4. Subjects whose results from the screening ACTH stimulation test are considered normal
             (cortisol level &gt;18 ug/dL at 30 minutes post stimulation) and show no other signs of
             abnormal HPA function or adrenal response.  -

        Exclusion Criteria:

          1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,
             exfoliative or pustular psoriasis.

          2. History of organ transplant requiring immunosuppression, HIV, or other
             immunocompromised state.

          3. Have received treatment for any type of cancer within 5 years of the Baseline Visit
             except skin cancer and cervical cancer (in situ) are allowed if at least 1 year
             before the Baseline Visit.

          4. Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g.,
             tacrolimus, pimecrolimus), or 2) systemic antipsoriatic treatment (e.g.,
             methotrexate, cyclosporine, hydroxyurea)

          5. Use within 30 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs
             (salicylic acid, anthralin, coal tar, calcipotriene)2) PUVA therapy, 3)  systemic
             anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine),
             or 4) UVB therapy.

          6. Use within 30 days prior to the Screening Visit of any product containing
             corticosteroids. Inhaled, intraocular, intranasal, etc. steroids are not allowed.

          7. Subjects who have an abnormal sleep schedule or work at night.

          8. Subjects with a known history of acute adrenal crisis, Addison's disease or decreased
             adrenal output, low pituitary function or pituitary tumors.

          9. Subjects who have a history of an adverse reaction to cosyntropin injection or
             similar test reagents.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kendra Gulbronson, MS</last_name>
    <phone>609-282-1476</phone>
    <email>kgulbronson@promiuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Dermatology and Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stacy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redwood Dermatology Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Sugarman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FXM Research Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hector Wiltz, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alicia Bucko, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zoe Diane Draelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Company, Inc.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer L Parish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael H Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Janet DuBois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adelaide Hebert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, PA The Center for Skin Research Katy/Cinco Ranch</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Syed Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
